Copley Acquisition terminates Ignite Proteomics merger; faces Nov 2, 2026 deal deadline

Copley Acquisition Corp

Mutual Termination Agreement dated Oct 9, 2026 ends the June 10, 2026 Business Combination Agreement with Ignite Proteomics, LLC effective immediately.
Copley intends to keep pursuing a business combination; it has until Nov 2, 2026, subject to extension, and cites risk of trust-account redemption and liquidation.
Only Sections 6.14, 6.15, 8.2, 9.1 and Article X of the BCA survive; all ancillary documents, including Seller Support Agreements, Insider Letter Amendment and Lock-Up Agreements, auto-terminated.
Each party bears its own fees and expenses incurred on the deal; the Termination Agreement includes mutual releases of all BCA-related claims, other than claims under the Termination Agreement.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.